Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 18/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6166935 | 0.78 | OPRM1 (0.39) | OPRM1HTTKMT2AHSD17B10OPRK1 | |
| SCHEMBL6165525 | 0.78 | HTT (0.61) | OPRM1HTTKMT2AHSD17B10OPRK1 | |
| SCHEMBL6166825 | 0.77 | OPRM1 (0.54) | OPRM1HTTKMT2AHSD17B10OPRK1 | |
| SCHEMBL15730601 | 0.77 | OPRM1 (0.54) | OPRM1HTTKMT2AHSD17B10HDAC1 | |
| SCHEMBL6162505 | 0.76 | ALPL (0.67) | OPRM1HTTKMT2AHSD17B10 | |
| SCHEMBL6164453 | 0.76 | HTT (0.64) | OPRM1HTTKMT2AHSD17B10OPRK1 | |
| SCHEMBL6163402 | 0.74 | ALPL (0.45) | OPRM1HTTKMT2AHSD17B10 | |
| SCHEMBL24402767 | 0.73 | OPRM1 (0.48) | OPRM1HTTKMT2AHSD17B10OPRK1 | |
| SCHEMBL6166305 | 0.73 | OPRM1 (0.76) | OPRM1HTTKMT2AHSD17B10OPRK1 | |
| SCHEMBL6770719 | 0.71 | OPRM1 (0.76) | OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354365-A1 | COMPOUNDS AND METHODS FOR TARGETING HSP90 | DUKE UNIVERSITY (US) | 2020-11-12 | — | — | US | disclosed |
| US-10442806-B2 | Substituted heterocycles for targeting HSP90 | DUKE UNIVERSITY (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190031661-A1 | COMPOUNDS AND METHODS FOR TARGETING HSP90 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-31 | — | — | US | disclosed |
| EP-1177185-B1 | 4, 5, 6, 7-TETRAHYDROINDAZOLE DERIVATIVES AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2005-04-20 | — | — | EP | disclosed |
| US-6716856-B1 | CELL PROLIFERATIVE DISORDERS OR ALZHEIMER'S DISEASE; REDUCED TOXICITY; CDK/CYCLIN KINASE INHIBITORY ACTIVITY | PHARMACIA & TUBJOHN SPA (IT) | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031661-A1 | COMPOUNDS AND METHODS FOR TARGETING HSP90 | HSP90AB1, HSP90B1, HSP90AB2P | OPRM1 4415/4885HTT 276/4885KMT2A 4427/4885 |
| US-20200354365-A1 | COMPOUNDS AND METHODS FOR TARGETING HSP90 | HSP90B1, HSP90AB1, HSP90AB2P | OPRM1 4329/4885HTT 414/4885KMT2A 4300/4885 |
| US-10442806-B2 | Substituted heterocycles for targeting HSP90 | HSP90AB1, HSP90AB2P, HSP90B1 | OPRM1 4530/4885HTT 540/4885KMT2A 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.